PET Imaging

Positron emission tomography (PET) is a nuclear imaging technology (also referred to as molecular imaging) that enables visualization of metabolic processes in the body. The basics of PET imaging is that the technique detects pairs of gamma rays emitted indirectly by a positron-emitting radionuclide (also called radiopharmaceuticals, radionuclides or radiotracer). The tracer is injected into a vein on a biologically active molecule, usually a sugar that is used for cellular energy. PET systems have sensitive detector panels to capture gamma ray emissions from inside the body and use software to plot to triangulate the source of the emissions, creating 3-D computed tomography images of the tracer concentrations within the body.

NMP to evaluate technology to create new class of PET radiopharmaceuticals
News | PET Imaging
Fuzionaire Radioisotope Technologies K.K. and Nihon Medi-Physics Enter Feasibility Study Agreement

January 29, 2021 — Fuzionaire Radioisotope Technologies K.K. (“FRIT”) announced that it has entered into a feasibility ...

Time January 29, 2021
arrow
Clinical utility of Axumin (fluciclovine F 18) being investigated in expanded areas of cancer imaging
News | PET Imaging
Blue Earth Diagnostics Announces Dosing of Initial Patient in Phase 3 REVELATE Clinical Trial of 18F-Fluciclovine PET Imaging for Detection of Recurrent Brain Metastases

January 18, 2021 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and ...

Time January 18, 2021
arrow
Differences in brain activity between connected and disconnected states of consciousness studied with positron emission tomography (PET) imaging. Activity of the thalamus, anterior (ACC) and posterior cingulate cortices (PCC), and bilateral angular gyri (AG) show the most consistent associa-tions with the state of consciousness (A = general anesthesia, B = sleep). The same brain struc-tures, which are deactivated when the state of consciousness changes to disconnected in general anesthesia or natural sleep
News | PET Imaging
Imaging the Twilight Zone

December 30, 2020 — What happens in the brain when our conscious awareness fades during general anesthesia and normal ...

Time December 30, 2020
arrow
A multidisciplinary team of researchers have demonstrated production, purification, and potential for the 134Ce/134La in vivo generator as a PET imaging surrogate for 225Ac and 227Th radiotherapeutic agents.
News | Nuclear Imaging
New Diagnostic Isotope to Enhance Targeted Alpha Therapy for Cancer

December 22, 2020 — Researchers in the DOE Isotope Program have developed an effective radionuclide, cerium-134, as a ...

Time December 22, 2020
arrow
CXCR4-directed PET correlates with MRI-determined lymphoma lesions. Depicted are representative MR images (T1c- and FLAIR- sequences), and the corresponding CXCR4- directed PET images and fusion images (MRI-FLAIR and PET), of two patients with PCNSL and SCNSL, respectively. Images created by Department of Nuclear Medicine, School of Medicine, Technische Universität München, Munich, Germany.
News | PET Imaging
PET Imaging Tracer Effective for Diagnosing and Managing Rare CNS B-cell Lymphoma

December 14, 2020 — Positron emission tomography (PET) imaging with 68Ga-pentixafor is an effective diagnostic tool for ...

Time December 14, 2020
arrow
News | Nuclear Imaging
The Journal of Nuclear Medicine Celebrates 60 Years of Research

December 14, 2020 — The Journal of Nuclear Medicine (JNM) has issued a special supplement commemorating six decades of ...

Time December 14, 2020
arrow
Videos | PET-CT
VIDEO: Example of PET-CT Artificial Intelligence Driven Image Reconstruction

This is an example of Canon's Advanced intelligent Clear-IQ Engine (AiCE) AI-driven image reconstruction software that ...

Time December 04, 2020
arrow
 Blue Earth Diagnostics, a leading molecular imaging diagnostics company, today announced that their manufacturing partner Nucleis (Liege, Belgium) has manufactured and shipped their first patient doses of rhPSMA-7.3 (18F), an investigational Prostate-Specific Membrane Antigen (PSMA)-targeted radiohybrid PET imaging agent, currently under evaluation in clinical trials in men with newly diagnosed prostate cancer and suspected prostate cancer recurrence.
News | PET Imaging
Blue Earth Diagnostics Announces First Patient Doses of PET Imaging Agent in Collaboration with Nucleis Radiopharmaceuticals

November 25, 2020 — Blue Earth Diagnostics, a leading molecular imaging diagnostics company, today announced that their ...

Time November 25, 2020
arrow
"Initial report of a randomized trial comparing conventional- vs conventional plus fluciclovine (18F) PET/CT imaging-guided post-prostatectomy radiotherapy for prostate cancer" was presented by Ashesh Jani, M.D., Winship Cancer Institute of Emory University, at ASTRO20
News | PET Imaging
Adding Advanced PET Scans to Radiation Treatment Plans for Prostate Cancer Increases Failure-free Survival Rates

October 26, 2020 — Adding the advanced PET radiotracer fluciclovine to conventional imaging to help guide radiation ...

Time October 26, 2020
arrow
During virtual RSNA 2020, Canon Medical Systems USA, Inc. will showcase enhancements to the Cartesion Prime PET/CT system, a premium Digital PET/CT scanner designed to help health care providers deliver more personalized care.
News | PET-CT
Cartesion Prime Helps Expand Enhanced Clinical Insights While Maximizing Business Performance

October 5, 2020 — During virtual RSNA 2020, Canon Medical Systems USA, Inc. will showcase enhancements to the Cartesion ...

Time October 05, 2020
arrow
RefleXion and Sofinnova Partners received the “Salus Partner Excellence in HealthTech Award” at the Convergence in Oncology Summit in Lausanne, Switzerland.  The prize recognizes RefleXion and Sofinnova Partner’s vision and excellence in developing the disruptive biology-guided radiotherapy (BgRT) for treatment of cancer patients.
News | PET Imaging
RefleXion and Sofinnova Partners recognized with Salus Excellence Award

September 25, 2020 — RefleXion and Sofinnova Partners received the “Salus Partner Excellence in HealthTech Award” at the ...

Time September 25, 2020
arrow
HABLE study prioritizes brain imaging and biomarker research among Mexican Americans.
News | PET Imaging
NIH Augments Large Scale Study of Alzheimer’s Disease Biomarkers

September 14, 2020 — To meet the pressing need to better understand the prevalence, progression, and clinical impact of ...

Time September 14, 2020
arrow
a) Includes scintigraphy and PET with and without concomitant CT. b) Includes conventional radiography, dual-energy x-ray absorptiometry, fluoroscopy, and radiography performed during radiologic interventions. c) Includes general, cardiothoracic, maxillary, plastic, and orthopedic surgery and neurosurgery. d) Includes allergology, cardiology, geriatrics, general internal medicine, pulmonology, gastroenterology, and rheumatology
News | Radiology Imaging
Unread Second-opinion Radiology Reports Waste Healthcare Resources

August 14, 2020 — According to ARRS' American Journal of Roentgenology (AJR), clinicians do not read a considerable ...

Time August 14, 2020
arrow
Tau (blue) and amyloid (orange) distribution patterns for super-agers, normal-agers and MCI patients, when compared to a group of younger, healthy, cognitively normal, amyloid-negative individuals. Brain projections are depicted at an uncorrected significance level of p < .0001. Color bars represent the respective t-statistic. Image courtesy of Merle C. Hoenig, Institute for Neuroscience and Medicine II - Molecular Organization of the Brain, Research Center Juelich, Juelich, Germany, and Department of Nucle
News | PET Imaging
SNMMI Image of the Year Features Super-agers

July 16, 2020 — Super-agers, or individuals whose cognitive skills are above the norm even at an advanced age, have been ...

Time July 16, 2020
arrow
Novel imaging agent provides foundation to inform treatment strategies
News | PET Imaging
Molecular Imaging Identifies Link Between Heart and Kidney Inflammation After Heart Attack

July 16, 2020 — Whole body positron emission tomography (PET) has, for the first time, illustrated the existence of ...

Time July 16, 2020
arrow
PSMA PET/CT accurately detects recurrent prostate cancer in 67-year-old man. 18F-DCFPyL-PSMA PET/CT shows extensive, intensely PSMA-avid local recurrence in prostate (bottom row; solid arrow) in keeping with the known tumor recurrence in the prostate. Right: PET shows extensive, intensely PSMA-avid local recurrence in prostate (top row; solid arrow) and a solitary bone metastasis in left rib 2 (bottom row; dotted arrow). Image courtesy of Ur Metser, et al.
News | PET-CT
PSMA PET/CT Can Change Management in Recurrent Prostate Cancer

July 16, 2020 — New research confirms the high impact of PSMA PET/CT in the detection and management of recurrent ...

Time July 16, 2020
arrow
Total-body dynamic 18F-FDG PET imaging with the uEXPLORER scanner allows us to monitor the spatiotemporal distribution of glucose concentration in metastatic tumors in the entire body (a). As compared to a typical clinical standardized uptake value image (b), the parametric image of FDG influx rate (Ki) can achieve higher lesion-to-background (e.g., the liver) contrast. In addition to glucose metabolism imaging by Ki, total-body dynamic PET also enables multiparametric characterization of tumors and organs
News | PET Imaging
Total-body Dynamic PET Successfully Detects Metastatic Cancer

July 16, 2020 — Results from the first study using uEXPLORER to conduct total-body dynamic positron emission tomography ...

Time July 16, 2020
arrow
PET/CT imaging showing uptake and retention of 86Y-NM600 (imaging agent) in immunocompetent mice bearing prostate tumors. PET imaging data was employed to estimate tumor dosimetry and prescribe an immunomodulatory 90Y-NM600 (therapy agent) injected activity. Image courtesy of R Hernandez et al., University of Wisconsin-Madison, WI.
News | PET-CT
Targeted Radionuclide Therapy Enhances Prostate Cancer Response to Immunotherapies

July 15, 2020 — Targeted radionuclide therapy has been found to create a favorable tumor microenvironment in prostate ...

Time July 15, 2020
arrow
Representative maximum-intensity projection PET images of a healthy human volunteer injected with 64Cu-NOTA-EB-RGD at 1, 8, and 24 hours after injection. Axial MRI and PET slices of glioblastoma patient injected with 64Cu-NOTA-EB-RGD at different time points after injection. Image courtesy of Jingjing Zhang et al., Peking Union Medical College Hospital, Beijing, China/ Xiaoyuan Chen et al., Laboratory of Molecular Imaging and Nanomedicine, NIBIB/NIH, Bethesda, USA
News | PET Imaging
New PET Radiotracer Proven Safe in Imaging Malignant Brain Tumors

July 15, 2020 — A first-in-human study presented at the Society of Nuclear Medicine and Molecular Imaging 2020 Annual ...

Time July 15, 2020
arrow
The FDA has approved Lilly’s TAUVID (flortaucipir F 18 injection), a radioactive diagnostic agent, for PET imaging of the brain to estimate the density and distribution of aggregated tau neurofibrillary tangles (NFTs) in adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease
News | Contrast Media
FDA Approves TAUVID for Use in Patients Being Evaluated for Alzheimer’s Disease

June 1, 2020 — TAUVID, a radioactive diagnostic agent, has been approved by the FDA for positron emission tomography ...

Time June 01, 2020
arrow
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now